MetaVia was incorporated under the laws of the State of Delaware in October 2014.
MetaVia’s principal offices are located at 545 Concord Avenue, Suite 210 Cambridge, MA 02138.
MetaVia Inc. became a publicly traded company on December 31, 2019, in connection with the reverse merger with Gemphire Therapeutics, Inc. (previously Nasdaq: GEMP), at which time the company changed its ticker symbol to NRBO. On November 29, 2024, the company changed its name to MetaVia and its ticker symbol to MTVA.
MetaVia’s stock is traded on the Nasdaq Capital Market under the symbol MTVA.
MetaVia’s fiscal year end is December 31st.
MetaVia’s CUSIP number is 64132R 404.
MetaVia’s stock transfer agent is Equiniti Trust Company LLC, 6201 15th Avenue. Brooklyn, New York 11219. You may reach an Equiniti Trust Company LLC representative by dialing (800) 937-5449 or by e-mail at admin1@equiniti.com. Who do I contact if I need to change the name of the registered holder, etc.? For lost stock certificates or to make changes to the name of the registered holder, please contact MetaVia’s stock transfer agent.
You can buy or sell shares of MetaVia (Nasdaq: MTVA) through a licensed stockbroker or by using an online account.
MetaVia does not currently pay any cash or other dividends. Management anticipates that it will retain all available funds and any future earnings, if any, for use in the operation of the business.
MetaVia’s independent auditors are BDO USA, LLP, located in Boston, Massachusetts.
MetaVia’s legal counsel is Honigman LLP.
You can access the latest corporate news through the Press Release section of the MetaVia website here and you can access financial information in the SEC Filing section of the MetaVia website SEC Filing section of the MetaVia here.
You can sign up for email alerts from MetaVia here..
For additional information on MetaVia, you can reach out to the Investor Relations contact: Michael Miller, Rx Communications Group, LLC, mmiller@rxir.com.